CommercialCoverageMedium impact
08.00.46e, Isatuximab-irfc (Sarclisa®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Mar 24, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.00.46e for Isatuximab-irfc (Sarclisa®) has been updated effective March 24, 2025 with changes to medical necessity criteria, medical coding, and general policy guidelines. The billing team must review updated coverage requirements and coding instructions for this oncology drug to ensure compliant claims submission.
Action Required
By March 24, 2025: Billing and clinical teams must access the full policy at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=03&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-00-46e to review updated medical necessity criteria, medical coding requirements, and guidelines for Isatuximab-irfc (Sarclisa®). Update billing system rules, prior authorization templates (if applicable), and clinical documentation requirements to align with the new criteria. Communicate changes to providers and pharmacy staff. Ensure all claims submitted on or after the effective date comply with the updated policy to avoid denials.